Physician profile
Kevin Waldron
NPI 1659314540
$933.30
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $118 · 2021: $219 · 2022: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $544.13 | 2019-2022 | |
| Abbott Laboratories | $104.07 | 2020-2021 | |
| Nuvasive, INC. | $84.58 | 2019-2021 | |
| Djo, LLC | $74.18 | 2019-2022 | |
| Medtronic USA, INC. | $40.87 | 2019 | |
| Zimmer Biomet Holdings, INC. | $33.04 | 2019 | |
| Bard Peripheral Vascular, INC. | $19.24 | 2021 | |
| Lemaitre Vascular, INC. | $17.24 | 2019 | |
| Livanova USA, INC. | $15.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Waldron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.